A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant

Human Gene Therapy

Volumn 10, Issue 11, 1999, Pages 1811-1818

  Yao, Feng ^a   Eriksson, Elof ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; GENE SWITCHING; GENE THERAPY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; NONHUMAN; PROTEIN EXPRESSION; REPRESSOR GENE; SEQUENCE ANALYSIS; VERO CELL; VIRUS GENOME; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; DNA-BINDING PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; RECOMBINATION, GENETIC; REPLICATION ORIGIN; REPRESSOR PROTEINS; TUMOR CELLS, CULTURED; VERO CELLS; VIRAL PROTEINS; VIRUS REPLICATION;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1;

EID: 0033587602     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017491     Document Type: Article

References (50)

1. ANDREANSKY, S.S., HE, B., GILLESPIE, G.Y., SOROCEANU, L., MARKET, J., CHOU, J., ROIZMAN, B., and WHITLEY, R.J. (1996). The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. U.S.A. 93, 11313-11318.
2. BEVEC, D., DOBROVNIK, M., HAUBER, J., and BOHNLEIN, E. (1992). Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc. Natl. Acad Sci. U.S.A. 89, 9870-9874.
3. BREAKEFIELD, X.O., and DELUCA, N.A. (1991). Herpes simplex virus for gene delivery to neurons. New Biol. 3, 3125-3128.
4. CAI, W., and SCHAFFER, P.A. (1989). Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA. J. Virol. 63, 4579-4589.
5. CHAMBERS, R., GILLESPIE, G.Y., SOROCEANU, L., ANDREANSKY, S., CHATTERJEE, S., CHOU, J., ROIZMAN, B., and WHITLEY, R.J. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma. Proc. Natl. Acad. Sci. U.S.A. 92, 1411-1415.
6. CHATTERJEE, S., JOHNSON, P.R., and WONG, K.K. (1992). Dual-target inhibition of HIV-1 in vitro by means of adeno-associated virus antisence vector. Science 258, 1485-1488.
7. CHIOCCA, E.A., CHOI, B.B., CAI, W., DELUCA, N.A., SCHAFFER, P.A., DIFIGLIA, M., BREAKEFIELD, X.O., and MARTUZA, R.L. (1990). Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol. 2, 739-746.
8. COEN, D.M., KOSZ-VNENCHAK, M., JACOBSON, J.G., LEIB, D.A., BOGARD, C.L., SCHAFFER, P.A., TYLER, K.L., and KNIPE, D.M. (1989). Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. U.S.A. 86, 4736-4740.
9. DEB, S., and DEB, S.P. (1991). A 269-amino-acid segment with a pseudo-leucine zipper and a helix-turn-helix motif codes for the sequence-specific DNA-binding domain of herpes simplex virus type 1 origin-binding protein. J. Virol. 65, 2829-2838.
10. DELUCA, N.A., and SCHAFFER, P.A. (1988). Physical and functional domains of the herpes simplex virus transcriptional regulatory protein ICP4. J. Virol. 62, 732-743.
11. DOBSON, A.T., MARGOLIS, T.P., SEDARATI, F., STEVENS, J.G., and FELDMAN, L.T. (1990). A latent, nonpathogenic HSV-1 derived vector stably expresses beta-galactosidase in mouse neurons. Neuron 5, 353-360.
12. s reside in the N-terminal part of the protein. J. Biol. Chem. 267, 17424-17429.
13. FINK, D.J., STERNBERG, L.R., WEBER, P.C., MATA, M., COINS, W.F., and GLORIOSO, J.C. (1992). In vivo expression of β-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum. Gene Ther. 3, 11-20.
14. GREEN, M., ISHINO, M., and LOEWENSTEIN, P.M. (1989). Mutational analysis of HIV-1 tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58, 215-223.
15. HAZUDA, D.J., PERRY, H.C., NAYLOR, A.M., and MCCLEMENTS, W.L. (1991). Characterization of the herpes simplex virus origin binding protein interaction with Oris. J. Biol. Chem. 261, 24621-24626.
16. HAZUDA, D.J., PERRY, H.C., and McCLEMENTS, W.L. (1992). Cooperative interactions between replication origin-bound molecules of herpes simplex virus origin-binding protein are mediated via the amino terminus of the protein. J. Biol. Chem. 267, 14309-14315.
17. HIRSCH, M.S. (1990). In Principles and Practice of Infectious Diseases. G.L. Mandell, R.G.J. Douglas, and J.E. Bennett, eds. (Churchill Livingstone, New York) pp. 1144.
18. JACOBSON, J.G., LEIB, D.A., GOLDSTEIN, D.J., BOGARD, D.L., SCHAFFER, P.A., WELLER, S.K., and COEN, D.M. (1989). A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173, 276-283.
19. KATZ, J.P., BODIN, E.T., and COEN, D.M. (1990). Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants. J. Virol. 64, 4288-4295.
20. KRAMM, C.M., RAINOV, N.G., SENA-ESTEVES, M., CHASE, M., PECHAN, P.A., CHIOCCA, E.A., and BREAKEFIELD, X.O. (1996). Herpes vector-mediated delivery of marker genes to disseminated CNS tumors. Hum. Gene Ther. 7, 291-300.
21. LIU, J., WOFFENDIN, C., YANG, Z.Y., and NABEL, G.J. (1994). Regulated expression of a dominant negative form of Rev improves resistance to HIV-1 replication in T cells. Gene Ther. 1, 32-37.
22. MACIEJEWSKI, J.P., WEICHOLD, F.F., YOUNG, N.S., ZELLA, C.D., REITZ, M.S., JR., and GALLO, R.C. (1995). Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Med. 1, 667-673.
23. MALIK, A.K., and WELLER, S.K. (1996). Use of transdominant mutants of the origin-binding protein (UL9) of herpes simplex virus type 1 to define functional domains. J. Virol. 70, 7859-7866.
24. MALIM, M.H., BOHNLEIN, S., HAUBER, J., and CULLEN, B.R. (1989). Functional dissection of the HIV-1 Rev trans-activator - derivation of a trans-dominant repressor of Rev function. Cell 58, 205-214.
25. MARTUZA, R.L., MALICK, A., MARKERT, J.M., RUFFNER, K.L., and COEN, D.M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
26. MCGEOCH, D.J., DALRYMPLE, M.A., DOLAN, A., McNAB, D., PERRY, L.J., TAYLOR, P., and CHALLBERG, M.D. (1988). Structures of herpes simplex virus type 1 genes required for replication of virus DNA. J. Virol. 62, 444-453.
27. MEIGNER, G., LONGNECKER, R., and ROIZMAN, B. (1988). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J. Infect. Dis. 3, 603-614.
28. MHASHILKAR, A.M., BAGLEY, J., CHEN, S.Y., SZILVAY, A.M., HELLAND, D.G., and MARASCO, W.A. (1995). Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 10, 1542-1551.
29. MINETA, T., RABKIN, S.D., YAZAKI, T., HUNTER, W.D., and MARTUZA, R.L. (1995). Attenuated multi-mutated herpes simplex virus 1 for treatment of malignant gliomas. Nature Med. 1, 938-943.
30. MORRISON, L.A., and KNIPE, D.M. (1994). Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection. J. Virol. 68, 689-696.
31. NGUYEN, L., KNIPE, D.M., and FINBERG, R.W. (1992). Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J. Virol. 66, 7067-7072.
32. OLIVO, P.D., NELSON, N.J., and CHALLBERG, M.D. (1989). Herpes simplex virus type 1 gene products required for DNA replication: Identification and overexpression. J. Virol. 63, 196-204.
33. PERRY, H.C., HAZUDA, D.J., and McCLEMENTS, W.L. (1993). The DNA binding domain of herpes simplex virus type 1 origin binding protein is a transdominant inhibitor of virus replication. Virology 193, 73-79.
34. + T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum. Gene Ther. 9, 487-496.
35. ROIZMAN, B. (1996). The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors. Proc. Natl. Acad. Sci. U.S.A. 93, 11307-11312.
36. ROIZMAN, B., and SEARS, A.E. (1990). In Virology, 2nd Ed. B.N. Fields et al., eds. (Raven, New York) pp. 1795-1841.
37. ROIZMAN, B., and SPECTOR, D. (1991). The induction of α genes by the α-trans-inducing factor. In Herpesvirus Transcription and Its Regulation. E. Wagner, ed. (CRC Press, Boca Raton, FL) pp. 105-135.
38. SCZAKIEL, G., and PAWLITA, M. (1991). Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J. Virol. 65, 468-472.
39. SHAHEEN, F., DUAN, L., ZHU, M., BAGASRA, O., and POMERANTZ, R.J. (1996). Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J. Virol. 70, 3392-3400.
40. STARR, P.A., LIM, F., GRANT, F.D., TRASK, L., LANG, P., YU, L., and GELLER, A.I. (1996). Long-term persistence of defective HSV-1 vectors in the rat brain is demonstrated by reactivation of vector gene expression. Gene Ther. 3, 615-623.
41. STOW, N.D. (1992). Herpes simplex virus origin-dependent replication in insect cells using recombinant baculoviruses. J. Gen. Virol. 73, 313-321.
42. STOW, N.D., HAMMARSTEN, O., ARBUCKLE, M., and ELIAS, P. (1993). Inhibition of herpes simplex virus type 1 DNA replication by mutant forms of the origin-binding protein. Virology 196, 413-418.
43. TRONO, D., FEINBERG, M.B., and BALTIMORE, D. (1989). HIV-1 gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59, 113-120.
44. VERES, G., JUNKER, U., BAKER, J., BARSKE, C., KALFOGLOU, C., ILVES, H., ESCAICH, S., KANESHIMA, H., and BOHNLEIN, E. (1998). Comparative analysis of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J. Virol. 72, 1894-1901.
45. WHITLEY, R.J. (1990). In Virology, 2nd Ed. B.N. Fields et al., eds. (Raven Press, New York) pp. 1843-1887.
46. 1 34.5 deletion mutants in rodent models. J. Clin. Invest. 91, 2837-2843.
47. YAO, F., and COURTNEY, R.J. (1989). A major transcriptional regulatory protein (ICP4) of herpes simplex virus type 1 is associated with purified virions. J. Virol. 63, 3338-3344.
48. YAO, F., and ERIKSSON, E. (1999). A novel tetracycline-inducible viral replication switch. Hum. Gene Ther. 3, 419-427.
49. YAO, F., and SCHAFFER, P.A. (1995). Cellular factor(s) specified by the osteosarcoma line, U2OS, can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J. Virol. 69, 6249-6258.
50. YAO, F., SEVENSJO, T., WINKER, T., LU, M., ERIKSSON, C., and ERIKSSON, E. (1998). Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum. Gene Ther. 9, 1939-1950.